Articles tagged with Heart Failure
A novel disease mechanism links circulating DPP3 to cardiac and renal dysfunction, with sustained high DPP3 levels associated with reduced cardiac function, impaired kidney function, and increased mortality. The DPP3 biomarker has high potential utility in diagnosing organ dysfunction and predicting outcomes in cardiogenic shock patients.
Procizumab shows high therapeutic potential in treating acute heart failure and cardiogenic shock by targeting the DPP3 enzyme. The company is setting up GMP process for Procizumab manufacturing and expects to enter regulatory non-clinical safety studies next year.
A new study published in The BMJ found that SGLT2 inhibitors, commonly used for type 2 diabetes, reduce the risk of heart failure by 34% compared to another type of diabetes drug. The study also showed a 20% lower risk of death among patients taking SGLT2 inhibitors.
A study of nearly 8,800 individuals found that quitting heavy smoking lowers the risk of cardiovascular disease within five years, but this benefit diminishes after 10 to 15 years compared to never-smokers. The analysis suggests a long-term risk premium for former smokers, limiting the generalizability of findings
Research reveals insomnia is tied to a higher risk of coronary artery disease, heart failure, and ischemic stroke. Genetic variants for insomnia were found to be associated with significantly higher odds of these conditions, emphasizing the importance of addressing sleep disorders.
Researchers at Medical College of Georgia have identified a chemical that can improve communication between the body's smallest blood vessels and larger vessels, which is crucial for delivering oxygen to the heart muscle. By blocking an enzyme that inhibits this chemical, they found that it can reduce diastolic heart failure symptoms.
A new study found that female offspring of women with polycystic ovary syndrome have an increased risk for developing cardiac dysfunction. Researchers linked maternal androgen excess and continuous exposure to male hormones during fetal life as contributing factors.
Researchers at UT Health San Antonio found that higher doses of spironolactone can prevent dialysis in selected heart failure patients who are not responding to conventional diuretics. The study showed significant improvement in urine output and breathing, suggesting potential for avoiding dialysis
Researchers at UTA and UT Southwestern are studying the mechanisms of exercise intolerance in heart failure patients with preserved ejection fraction (HFpEF) to develop personalized therapies. They aim to identify common characteristics among HFpEF patients based on cardiac, pulmonary, and skeletal muscle limitations.
A global study of 12 million people found diabetes increases the risk of heart failure, with a significant increase for women. Women with type 1 diabetes have a 47% greater excess risk of heart failure compared to men, highlighting the need for sex-specific research.
Pierre will explore a new Na/K-ATPase/Src pathway to limit cardiac dysfunction in hopes of developing new therapeutic interventions. The study aims to test two distinct interventions in both acute and chronic phases of myocardial infarction.
A new study finds that diabetes confers a greater excess risk of heart failure in women than men, with type 1 diabetes associated with a 47% higher risk. The study suggests several potential explanations for this difference, including sex differences in diabetes management and cardiovascular risk factors.
A global study of 12 million people found that diabetes significantly increases the risk of heart failure, with women at greater risk than men. Type 1 and type 2 diabetes both pose a stronger risk for women, highlighting the need for sex-specific research into diabetes and its impact on heart health.
A study using Veterans Affairs data found that patients with heart failure have a higher risk of death and complications after undergoing noncardiac surgery. The researchers compared over 355,000 patients with and without heart failure to identify these risks.
A large health insurance database analysis reveals people living with HIV have a significantly higher risk of heart failure and stroke. Researchers found a 3.2-times increased risk of heart failure and 2.7-times increased risk of stroke in those living with HIV compared to uninfected individuals.
Researchers found that methylmercury increases cardiac fragility by removing an inhibitory brake on Drp1, a protein involved in mitochondrial fission. Treatment with a polysulfide group-releasing compound reversed this effect, suggesting a possible strategy to mitigate cardiotoxicity.
Researchers at Stanford University School of Medicine have created a map of gene activity and connectivity as the heart shuts down. The study identified PPP1R3A as a central regulator in heart failure, linked to metabolism of glucose within cells.
A new study found that cardiac resynchronization therapy with defibrillator (CRT-D) may improve heart function in certain groups of heart failure patients, particularly those with nonspecific intraventricular conduction delay (NICD) and a QRS duration of more than 150 milliseconds. In these patients, CRT-D was associated with decreased...
A recent study found that over half of relapsed multiple myeloma patients treated with carfilzomib experienced cardiac issues during treatment. The study recommends routine monitoring with natriuretic peptide testing to mitigate this risk.
Research published by the American Heart Association found that pre-treated patients with off-label selective vasodilator drugs are more likely to develop right-sided heart failure after LVAD implantation, increasing their risk of worse outcomes.
The American Heart Association and the Heart Failure Society of America issue a statement on managing both conditions, highlighting lifestyle modifications and multidisciplinary care teams. The guidelines emphasize the importance of coordinated treatment to improve patient outcomes.
A survey shows a wide variation in UK heart failure care, with some areas having fewer than seven nurses per 1,600 patients. Many services lack administrative support and mental health professionals, despite updated guidelines recommending best practice for diagnosis and management.
A new blood test that measures multiple proteins could provide a more accurate diagnosis of heart failure, allowing for earlier treatment and improved outcomes. Researchers are now collecting further samples to confirm the accuracy of this protein-based test.
A recent study by Dr. Ganesh Halade and colleagues found that lipoxygenase deficiency delays heart failure progression and improves survival in mice. The researchers discovered that epoxyeicosatrienoic acids facilitate cardiac healing after a heart attack, reducing diabetes risk biomarkers and altering plasma metabolic signaling.
A study found that elderly patients with heart failure who visit a pharmacist weekly are more likely to take their medications and be active, resulting in improved quality of life. The intervention increased adherence by 86% compared to usual care.
Patients with stable chronic heart failure can safely discontinue diuretics without increased dyspnoea or reuse of the medication. The ReBIC-1 trial found no significant differences in symptom relief between patients who stopped and those who continued taking furosemide.
Patients with chronic heart failure are more likely to adopt lifestyle advice when accompanied by family members, according to a new study. The study found that nearly 48% of patients did no physical activity and 25% never adhered to fluid restrictions.
A new study reveals that women undergoing fertility treatment are at a higher risk of peripartum cardiomyopathy (PPCM), a life-threatening condition. PPCM affects about one in 1,000 pregnant women worldwide and is characterized by an enlarged and weak heart, leading to symptoms such as shortness of breath and swelling.
A study found that biomarkers like midregional proadrenomedullin and bio-adrenomedullin can predict mortality risk in acute heart failure patients. Patients with these biomarker levels above the median had significantly lower survival if not receiving diuretics at discharge.
Researchers found that being an occupant in a motor vehicle accident increases the risk of heart failure or stroke in older adults. The study used U.S. and Danish hospitalization data to confirm these findings.
Researchers identified a protein called gravin as key to regulating beta-adrenergic receptor expression on heart cells. Elevated adrenaline levels in heart failure desensitize receptors, reducing heart function. Researchers seek to develop treatment targeting this mechanism.
A novel therapeutic approach occluding the superior vena cava shows promise in reducing pressure and volume in heart failure patients. The treatment improves cardiac filling pressures and function without affecting systemic blood pressure or output.
A study of over 8,000 participants found that elevated troponin I levels are associated with cardiac outcomes like heart attacks and fatal coronary disease. Adding troponin I to a risk prediction model improves accuracy in predicting heart failure risk, highlighting the potential for improved treatment strategies.
A study found that UK heart failure patients receive suboptimal care, with gaps in screening, follow-up, and medication doses disproportionately affecting women and older individuals. The study suggests improvements are needed in health services design to support high-quality care.
A UK study of 93,000 adults with heart failure reveals diagnostic tests, drug prescriptions, and follow-up patterns are suboptimal, particularly for women and those over 75 years old. The research highlights the need for improved care systems to address these gaps in chronic disease management.
A machine learning algorithm using eight variables has been developed to predict sudden cardiac death and heart failure death in heart failure patients. The study found a high accuracy rate of 0.87 for predicting all events, and 0.74 and 0.91 for arrhythmic events and heart failure death respectively.
A study of over 4,500 participants found that those under 75 who closely followed the DASH diet had a significantly lower risk of developing heart failure. The research suggests that the DASH diet can reduce heart failure risk by almost half, making it a promising element in primary prevention.
A recent survey reveals that nearly half of the public incorrectly believes heart failure is a normal part of aging, highlighting low awareness among both patients and the general public. Exercise has been found to be beneficial for patients with heart failure, with over half recognizing its potential as a treatment option.
Death rates due to heart failure are increasing among younger adults under 65, with black men under age 65 facing the largest increase in premature death. The study found that an estimated 6 million adults in the US have heart failure, which is the number one reason older adults are admitted to hospital.
A study presented at EuroHeartCare 2019 found that fitter heart failure patients have healthier brain function and are less likely to have cognitive impairment. Exercise has been shown to improve cognition in older adults and may also benefit heart failure patients.
A new study highlights the growing need for cardio-oncology services to monitor and prevent heart disease in cancer patients. The research found that many cancer survivors are not fully aware of the risks of cardiotoxicity and lack understanding of a balanced diet, making them more susceptible to heart failure.
Researchers have found that the drug Tadalafil, used to treat erectile dysfunction, slows or even reverses the progression of heart failure in sheep. The study suggests that the drug may also be effective in humans, offering new hope for treatment of this devastating condition.
A new study of 2.8 million UK adults found that higher BMI is associated with a significant increase in the risk of type 2 diabetes, sleep apnoea, heart failure, high blood pressure, and premature death. Adults with severe obesity class III are 12 times as likely to develop type 2 diabetes.
Researchers aim to understand molecular mechanisms behind dilative cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), two leading causes of heart failure. The study seeks to identify key genes and proteins involved in these conditions.
Researchers found a significant reduction in strokes and heart attacks with low-dose blood thinner use in patients with worsening heart failure or coronary artery disease. The study, published in JAMA Cardiology, suggests that this strategy may improve outcomes for patients at risk of subsequent issues.
A new study found that plant-based diets can lower the risk of heart failure in adults without known heart disease, while Southern diets are linked to higher risk. The study examined five dietary patterns and their association with incident heart failure hospitalizations.
Empagliflozin improved heart function, reduced pulmonary congestion, and enhanced systolic function in pigs with induced heart failure. The drug addressed heart failure by improving cardiac metabolism, boosting energy production and reducing glucose consumption.
A breakthrough treatment has been found to protect against kidney failure and cardiovascular complications in people with diabetes. The study showed a significant reduction in kidney failure and cardiovascular events, such as heart attacks and strokes, by up to 30%.
A team of UT Southwestern researchers has created a groundbreaking two-hit model to combat HFpEF, a type of heart failure with no effective treatments. By combining high-fat diets with blood pressure-raising drugs, they replicated the human condition and provided an accurate biological picture that can advance treatment development.
A combination of over-the-counter antioxidants shows promise for mitigating damaging effects of heart failure with preserved ejection fraction. Treatment improved markers of vascular function and inflammation in some patients, suggesting a simple and readily available option to improve vascular health.
A study found that heart failure patients are more likely to use the medication ivabradine when it is prescribed before hospital discharge. This can lead to a reduction in heart rate and improved outcomes. However, adoption of the therapy has been slow due to high cost and provider lack of familiarity.
A University of Guelph study found that the circadian mechanism affects cognition and mood in heart failure patients, suggesting ways to prevent and treat both conditions. The research may lead to new strategies to improve patients' quality of life.
A new study by NYU School of Medicine found that shorter stays in skilled nursing facilities (SNFs) are associated with a higher risk of hospital readmission among elderly heart failure patients. Patients who stayed at SNFs for two days or less had a risk four times higher than those who stayed longer.
Researchers at Ohio State University College of Medicine have identified a metabolic process in the heart that, if treated, could prevent or slow the progression of heart failure. By normalizing a reactive fat compound called acyl-CoA, the hearts retained their ability to burn fat and generate energy.
The CardioMEMS sensor reduced heart failure hospitalizations by 58% across all patient groups, including women and minorities. The device also lowered rates of all-cause hospitalizations for conditions like pneumonia and chronic obstructive pulmonary disease.
Researchers at UT Health San Antonio have created a smarter automatic defibrillator that accurately tracks stroke volume in addition to ECG readings. This update aims to deliver shocks only when needed, potentially preventing traumatic shocks and improving patient outcomes.
Patients with heart failure and a leaking heart valve who underwent transcatheter mitral valve repair reported significant improvements in quality of life after two years. The study found that patients treated with the procedure had better rates of survival and fewer symptoms, leading to improved daily activities.
A new study by the European Society of Cardiology found that a more precise placement of the left ventricular lead improves cardiac resynchronisation therapy (CRT) outcomes. The trial compared two methods for positioning the lead and found an absolute increase in left ventricular ejection fraction of 4% with electrical guidance.
Dapagliflozin significantly decreases rates of death from cardiovascular causes and death from all causes among patients with reduced ejection fraction. It also reduces heart failure hospitalizations across all patients, regardless of ejection fraction or heart failure status.
A recent study found that remote monitoring of implanted defibrillators in heart failure patients significantly reduces the rate of hospitalization and death. The trial showed a lower rate of primary endpoint (39.5%) compared to standard care (48.5%), with reduced cardiovascular deaths and hospitalizations.